Novel Phytochemical Constituents and their Potential to Manage Diabetes

2020 ◽  
Vol 26 ◽  
Author(s):  
Shaik Ibrahim Khalivulla ◽  
Arifullah Mohammed ◽  
Kokkanti Mallikarjuna
Keyword(s):  
Natural Products ◽  
Large Population ◽  
World Health ◽  
In Vivo Studies ◽  
Antidiabetic Activity ◽  
Therapeutic Drug ◽  
Pharmacological Activities ◽  
Chemical Structures

Background: Diabetes is a chronic disease affecting a large population worldwide and stands as one of the major global health challenges to be tackled. According to World Health Organization, about 400 million are having diabetes worldwide and it is the seventh leading cause of deaths in 2016. Plant based natural products had been in use from ancient time as ethnomedicine for the treatment of several diseases including diabetes. As a result of that, there are several reports on plant based natural products displaying antidiabetic activity. In the current review, such antidiabetic potential compounds reported from all plant sources along with their chemical structures are collected, presented and discussed. This kind of reports are essential to pool the available information to one source followed by statistical analysis and screening to check the efficacy of all known compounds in a comparative sense. This kind of analysis can give rise to few numbers of potential compounds from hundreds, whom can further be screened through in vitro and in vivo studies, and human trails leading to the drug development. Methods: Phytochemicals along with their potential antidiabetic property were classified according to their basic chemical skeleton. The chemical structures of all the compounds with antidiabetic activities were elucidated in the present review. In addition to this, the distribution and their other remarkable pharmacological activities of each species is also included. Results: The scrutiny of literature led to identification of 44 plants with antidiabetic compounds (70) and other pharmacological activities. For the sake of information, the distribution of each species in the world is given. Many plant derivatives may exert antidiabetic properties by improving or mimicking the insulin production or action. Different classes of compounds including sulfur compounds (1-4), alkaloids (5-11), phenolic compounds (12-17), tannins (18-23), phenylpropanoids (24-27), xanthanoids (28-31), amino acid (32), stilbenoid (33), benzofuran (34), coumarin (35), flavonoids (36-49) and terpenoids (50-70) were found to be active potential compounds for antidiabetic activity. Of the 70 listed compounds, majorly 17 compounds are from triterpenoids, 13 flavonoids and 7 are from alkaloids. Among all the 44 plant species, maximum number (7) of compounds are reported from Lagerstroemia speciosa followed by Momordica charantia (6) and S. oblonga with 5 compounds. Conclusion: This is the first paper to summarize the established chemical structures of phytochemicals that have been successfully screened for antidiabetic potential and their mechanisms of inhibition. The reported compounds could be considered as potential lead molecules for the treatment of type-2 diabetes. Further, molecular and clinical trials are required to select and establish the therapeutic drug candidates.

scholarly journals Nanomedicine Based on Natural Products: Improving Clinical Application Potential

2022 ◽  
Vol 2022 ◽  
pp. 1-11
Author(s):  
Zhe Li ◽  
Tingting Zhao ◽  
Jiaxin Li ◽  
Qingying Yu ◽  
Yu Feng ◽  
...  
Keyword(s):  
Natural Products ◽  
Clinical Application ◽  
Medical Application ◽  
In Vivo Studies ◽  
Research Progress ◽  
Pharmacological Activities ◽  
Application Potential ◽  
Clinical Transformation

Natural products have antitumor, anti-inflammatory, antioxidant, and other pharmacological activities and are an important source of drugs for prevention and treatment of various diseases. However, the inherent defects of natural products in physiological media such as poor solubility and stability and short biological half-life limit their clinical application. In recent years, more and more attention has been paid to the science of drug delivery by nanoscale materials. A large number of in vitro and in vivo studies have further confirmed the efficacy and safety of nanomedicine based on natural products in preclinical models of various diseases. In this review, we summarized the achievements of nanomaterials in improving the efficacy of natural products, introduced the research progress in several key fields of natural product-based nanomedicine in medical application, and discussed the challenges and prospects of clinical transformation of nanomedicine.

scholarly journals Chemical structures of phenylethanoid glycosides from Pedicularis species, their biological and pharmacological activities

2019 ◽  
pp. 54-60
Author(s):  
Nyamsuren E ◽  
Odontuya G
Keyword(s):  
Functional Group ◽  
Antioxidant Effect ◽  
In Vivo Studies ◽  
Phenylethanoid Glycosides ◽  
Pharmacological Activities ◽  
Chemical Structures ◽  
Structure Specification ◽  
Biological And Pharmacological Activities

In this review, we summarized the molecular structure specification of a unique component named as phenylethanoid glycosides from the genus Pedicularis L. and their biological and pharmacological activities. Until now, 40 phenylethanoid glycosides have been isolated and identified from the genus Pedicularis L. We classified the compounds into 4 main groups based on the functional group located at the 4′ position. According to the results of in vitro and in vivo studies, the extract containing phenylethanoid glycosides possesses antioxidative, antibacterial, anti-tumor and anti-fatigue activities as well as the increase in physical ability, hepatoprotection, and other effects. The antioxidant effect is the main biological activity of phenylethanoid glycosides. Хувилангын зүйл ургамлуудын фенилэтаноид гликозидуудын химийн бүтэц, биолог, фармакологийн идэвх Хураангуй: Бид энэхүү тойм өгүүлэлдээ Хувилангын (Pedicularis L.) төрөлд хамаарах ургамлуудын өвөрмөц бүрэлдэхүүн болох фенилэтаноид гликозидийн молекулын бүтцийн онцлог, тэдгээрийн биолог, фармакологийн идэвхийн судалгааны дүнг нэгтгэн бичлээ. Өнөөг хүртэл Хувилангын зүйл ургамлуудаас 40 фенилэтаноид гликозидийг ялгаж, бүтэц байгууламжийг тогтоосон байна. Бид тэдгээр бодисын молекулын бүтцэд дүн шинжилгээ хийж 4′ байрлал дахь халагч бүлэгт үндэслэн 4 бүлэгт ангилав. Фенилэтаноид гликозид зонхилонагуулагддаг ханд нь исэлдэлтийн эсрэг, бактер, хорт хавдрын эсийн өсөлтийг дарангуйлах идэвхтэй, ядралт багасгах, булчингийн үйл ажиллагааг дэмжих, элэг, тархийг гэмтэхээс хамгаалах үйлдэл үзүүлж байгаа нь in vitro ба in vivo туршилт судалгааны дүн харуулж байна. Исэлдэлтийг дарангуйлах үйлдэл бол фенилэтаноид гликозидуудын гол биологийн идэвх юм.Түлхүүр үг: Хувиланга, фенилэтаноид гликозид, каффейны хүчил, исэлдэлт дарангуйлах идэвх.

Modulation of Matrix Metalloproteinases by Plant-Derived Products

2020 ◽  
Vol 20 ◽  
Author(s):  
Nur Najmi Mohamad Anuar ◽  
Nurul Iman Natasya Zulkafali ◽  
Azizah Ugusman
Keyword(s):  
Clinical Trials ◽  
Natural Products ◽  
Matrix Metalloproteinases ◽  
Animal Studies ◽  
Current Knowledge ◽  
In Vitro Models ◽  
In Vivo Studies ◽  
Extracellular Matrix Components

: Matrix metalloproteinases (MMPs) are a group of zinc-dependent metallo-endopeptidase that are responsible towards the degradation, repair and remodelling of extracellular matrix components. MMPs play an important role in maintaining a normal physiological function and preventing diseases such as cancer and cardiovascular diseases. Natural products derived from plants have been used as traditional medicine for centuries. Its active compounds, such as catechin, resveratrol and quercetin, are suggested to play an important role as MMPs inhibitors, thereby opening new insights into their applications in many fields, such as pharmaceutical, cosmetic and food industries. This review summarises the current knowledge on plant-derived natural products with MMP-modulating activities. Most of the reviewed plant-derived products exhibit an inhibitory activity on MMPs. Amongst MMPs, MMP-2 and MMP-9 are the most studied. The expression of MMPs is inhibited through respective signalling pathways, such as MAPK, NF-κB and PI3 kinase pathways, which contribute to the reduction in cancer cell behaviours, such as proliferation and migration. Most studies have employed in vitro models, but a limited number of animal studies and clinical trials have been conducted. Even though plant-derived products show promising results in modulating MMPs, more in vivo studies and clinical trials are needed to support their therapeutic applications in the future.

A review on Remdesivir: A broad-spectrum antiviral molecule for possible COVID-19 treatment

2021 ◽  
Vol 21 ◽  
Author(s):  
Jabeena Khazir ◽  
Tariq Maqbool ◽  
Bilal Ahmad Mir
Keyword(s):  
Clinical Trials ◽  
Broad Spectrum ◽  
Ebola Virus ◽  
Controlled Trial ◽  
In Vivo Studies ◽  
Therapeutic Drug ◽  
Viral Agent ◽  
Double Blind

: Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), a novel coronavirus strain and the causative agent of COVID-19 was identified to have emerged in Wuhan, China, in December 2019 [1]. This pandemic situation and magnitude of suffering has led to global effort to find out effective measures for discovery of new specific drugs and vaccines to combat this deadly disease. In addition to many initiatives to develop vaccines for protective immunity against SARS-CoV-2, some of which are at various stages of clinical trials researchers worldwide are currently using available conventional therapeutic drugs with potential to combat the disease effectively in other viral infections and it is believed that these antiviral drugs could act as a promising immediate alternative. Remdesivir (RDV), a broad-spectrum anti-viral agent, initially developed for the treatment of Ebola virus (EBOV) and known to show promising efficiency in in vitro and in vivo studies against SARS and MERS coronaviruses, is now being investigated against SARS-CoV-2. On May 1, 2020, The U.S. Food and Drug Administration (FDA) granted Emergency Use Authorization (EUA) for RDV to treat COVID-19 patients [2]. A number of multicentre clinical trials are on-going to check the safety and efficacy of RDV for the treatment of COVID-19. Results of published double blind, and placebo-controlled trial on RDV against SARS-CoV-2, showed that RDV administration led to faster clinical improvement in severe COVID-19 patients compared to placebo. This review highlights the available knowledge about RDV as a therapeutic drug for coronaviruses and its preclinical and clinical trials against COVID-19.

Hemoglobin F (HbF) inducers; History, Structure and Efficacies

2021 ◽  
Vol 21 ◽  
Author(s):  
Zahra Hashemi ◽  
Mohammad Ali Ebrahimzadeh
Keyword(s):  
Clinical Trials ◽  
Natural Products ◽  
Biological Activities ◽  
Globin Gene ◽  
Beta Thalassemia ◽  
Gene Promoters ◽  
Hemoglobin F ◽  
Chemical Structures

Abstract: Inherited beta-thalassemia is a major disease caused by irregular production of hemoglobin through reducing beta-globin chains. It has been observed that increasing fetal hemoglobin (HbF) production improves symptoms in the patients. Therefore, an increase in the level of HbF has been an operative approach for treating patients with beta-thalassemia. This review represents compounds with biological activities and pharmacological properties that can promote the HBF level and therefore used in the β-thalassemia patients' therapy. Various natural products with different mechanisms of action can be helpful in this medication cure. Clinical trials were efficient in improving the signs of patients. Association of in vivo, and in vitro studies of HbF induction and γ-globin mRNA growth displays that in vitro experiments could be an indicator of the in vivo response. The current study shows that; (a) HbF inducers can be grouped in several classes based on their chemical structures and mechanism of actions; b) According to several clinical trials, well-known drugs such as hydroxyurea and decitabine are useful HbF inducers; (c) The cellular biosensor K562 carrying genes under the control of the human γ-globin and β-globin gene promoters were applied during the researches; d) New natural products and lead compounds were found based on various studies as HbF inducers.

scholarly journals Normal mouse peritoneum contains a large population of Ly-1+ (CD5) B cells that recognize phosphatidyl choline. Relationship to cells that secrete hemolytic antibody specific for autologous erythrocytes.

1988 ◽  
Vol 168 (2) ◽  
pp. 687-698 ◽  
Author(s):  
T J Mercolino ◽  
L W Arnold ◽  
L A Hawkins ◽  
G Haughton
Keyword(s):  
B Cells ◽  
Cell Surface ◽  
Phosphatidyl Choline ◽  
Large Population ◽  
In Vivo Studies ◽  
Antigen Specificity ◽  
Adult Mice ◽  
Large Numbers

We have found that, in the peritoneums of normal adult mice, 5-15% of lymphocytes bind a fluorescent liposome probe. In ontogeny, cells with this specificity were shown to appear by 8 d after birth, and increase to the adult frequency by 2-3 wk. Some older mice contain an expanded population of these cells. We have shown that liposome binding occurs by cell surface IgM recognizing the common membrane phospholipid, phosphatidyl choline (PtC). Virtually all of these PtC-specific cells bear the cell surface marker Ly-1. Our results indicate that roughly 1 in 10 peritoneal Ly-1+ B cells has this single specificity. We have found that the precursors to all the cells that form plaques on protease-treated autologous erythrocytes (BrMRBC) are included in the PtC-specific population and can be isolated by FACS. We believe this is the first report of sorting large numbers of B cells with a single antigen specificity from normal, unimmunized animals. This method will allow for in vitro and in vivo studies of differentiative and proliferative properties of Ly-1+ B cells, which may help define their role in development and disease.

scholarly journals Impetigo Animal Models: A Review of Their Feasibility and Clinical Utility for Therapeutic Appraisal of Investigational Drug Candidates

Antibiotics ◽  
2020 ◽  
Vol 9 (10) ◽  
pp. 694
Author(s):  
Solomon Abrha ◽  
Andrew Bartholomaeus ◽  
Wubshet Tesfaye ◽  
Jackson Thomas
Keyword(s):  
Animal Models ◽  
In Vivo Studies ◽  
Therapeutic Drug ◽  
Investigational Drug ◽  
Skin Infections ◽  
Drug Candidates ◽  
First Line Therapy ◽  
Superficial Skin

Impetigo (school sores), a superficial skin infection commonly seen in children, is caused by the gram-positive bacteria Staphylococcus aureus and/or Streptococcus pyogenes. Antibiotic treatments, often topical, are used as the first-line therapy for impetigo. The efficacy of potential new antimicrobial compounds is first tested in in vitro studies and, if effective, followed by in vivo studies using animal models and/or humans. Animal models are critical means for investigating potential therapeutics and characterizing their safety profile prior to human trials. Although several reviews of animal models for skin infections have been published, there is a lack of a comprehensive review of animal models simulating impetigo for the selection of therapeutic drug candidates. This review critically examines the existing animal models for impetigo and their feasibility for testing the in vivo efficacy of topical treatments for impetigo and other superficial bacterial skin infections.

scholarly journals Neuroprotective Strategies for Neurological Disorders by Natural Products: An update

2019 ◽  
Vol 17 (3) ◽  
pp. 247-267 ◽  
Author(s):  
Muneeb U. Rehman ◽  
Adil Farooq Wali ◽  
Anas Ahmad ◽  
Sheeba Shakeel ◽  
Saiema Rasool ◽  
...  
Keyword(s):  
Natural Products ◽  
Large Scale ◽  
Biological Properties ◽  
In Vivo Studies ◽  
Preclinical Models ◽  
Neuroprotective Effects ◽  
Neuroprotective Strategies ◽  
Inflammatory Processes

Nature has bestowed mankind with surplus resources (natural products) on land and water. Natural products have a significant role in the prevention of disease and boosting of health in humans and animals. These natural products have been experimentally documented to possess various biological properties such as antioxidant, anti-inflammatory and anti-apoptotic activities. In vitro and in vivo studies have further established the usefulness of natural products in various preclinical models of neurodegenerative disorders. Natural products include phytoconstituents, like polyphenolic antioxidants, found in herbs, fruits, nuts, vegetables and also in marine and freshwater flora. These phytoconstituents may potentially suppress neurodegeneration and improve memory as well as cognitive functions of the brain. Also, they are known to play a pivotal role in the prevention and cure of different neurodegenerative diseases, such as Alzheimer’s disease, epilepsy, Parkinson’s disease and other neuronal disorders. The large-scale neuro-pharmacological activities of natural products have been documented due to the result of either the inhibition of inflammatory processes, or the up-regulation of various cell survival proteins or a combination of both. Due to the scarcity of human studies on neuroprotective effects of natural products, this review focuses on the various established activities of natural products in in vitro and in vivo preclinical models, and their potential neuro-therapeutic applications using the available knowledge in the literature.

Prospective Function of Different Antioxidant Containing Natural Products in the Treatment of Neurodegenerative Disease

2020 ◽  
Vol 19 ◽  
Author(s):  
Md. Habibur Rahman ◽  
Rokeya Akter ◽  
Mohammad Amjad Kamal
Keyword(s):  
Natural Products ◽  
Large Scale ◽  
In Vivo Studies ◽  
Preclinical Models ◽  
Inflammatory Processes ◽  
Cognitive Actions ◽  
Neuro Protection ◽  
Neuronal Disorders

: Nature has bestowed humanity through additional resources natural products (NPs) on earth with water. However, NPs have a significant function in the avoidance of disease by boosting health in humans as well as animals. These NPs have been scientifically acknowledged to have a range of biological characteristics like antioxidant, anti-inflammatory actions. Both In vitro and in vivo studies have more recognised the convenience of NPs in different preclinical models of neurodegenerative disorders. Moreover, most NPs comprise phytoconstituents, including polyphenolic antioxidants; originate in herbs, fruits, nuts, vegetables as well as also in marine with freshwater flora. These phytoconstituents might actively repress neuro-degeneration and recover memory as like cognitive actions of the brain. Moreover, they are well recognized to participate in an essential position in the prevention like heal of different neurodegenerative diseases, like Alzheimer’s disease, Parkinson’s disease, epilepsy, and additional neuronal disorders. In general, the large-scale neuro-pharmacological actions of NPs have been familiar owing to the consequence of also the inhibition of inflammatory processes, or the up-regulation of various cell endurance proteins or a mixture of together. Owing to the shortage of human studies on neuroprotective belongings of NPs, this review highlights a variety of documented actions of NPs in vitro and in vivo preclinical models and their possible neuro-protection applications by the accessible awareness in writing.

Review on Adverse effects or side effects of Remdisivir

2021 ◽  
pp. 162-166
Author(s):  
Ganesh G. Dhakad ◽  
Rohit V. Patil ◽  
Tejas I. Chaudhari ◽  
Paresh A. Patil.
Keyword(s):  
Side Effects ◽  
Ebola Virus ◽  
Clinical Symptoms ◽  
Virus Disease ◽  
Clinical Status ◽  
World Health ◽  
In Vivo Studies ◽  
Rater Agreement

In March 2020, the World Health Organization declared the spread of SARS-CoV-2 a global pandemic. To date, coronavirus disease-2019 (COVID-19) has spread to over 200 countries, leading to over 1.6 million cases and over 99,000 deaths. Given that there is neither a vaccine nor proven treatment for COVID-19, there is currently an urgent need for effective pharmacotherapy. To address the need for an effective treatment of SARS-CoV-2 during the worldwide pandemic, this systematic review of intravenous (IV) remdesivir was performed. Remdesivir, an anti-viral prodrug originally developed to treat Ebola virus disease, has shown broad spectrum activity against the Coronavirus family. A recent case report reported improvement of clinical symptoms with remdesivir in a patient with COVID-19. After conducting a systematic search of 18 clinical trial registries and three large scientific databases, we identified 86 potentially eligible items. Following removal of duplicates (n = 21), eligible studies were reviewed independently by two authors. After the first round of screening, inter-rater agreement was 98.5% (κ = 0.925). After the second round of full-text screening, inter-rater agreement was 100%. A total of seven ongoing and recruiting clinical trials of remdesivir (100–200 milligrams, intravenous [IV]) were included. We identified the following primary outcomes: patients discharged (n = 2); time to clinical status improvement (n = 2); improved O2 saturation (n = 2); body temperature normalization (n = 2); and clinical status (n = 1). Secondary outcomes in all identified studies included documentation of adverse events. Phase 3 trials are expected to be completed between April 2020–2023. Therefore, despite supportive data from in vitro and in vivo studies, the clinical effectiveness of IV remdesivir for treatment of COVID-19 and potential side effects remain incompletely defined in the human population. But the remdesivir is also harmful for the people because of it can have some side effects such as mentioned in the following information. There are so many type of disease started form the treatment of COVID-19 with the Remdesivir that also mentioned in the following review paper.

Sign in / Sign up

Export Citation Format

Share Document